Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Breast Cancer Polygenic-Risk Score Influence on Risk-Reducing Endocrine Therapy Use: Genetic Risk Estimate (GENRE) Trial 1-Year and 2-Year Follow-Up.

Cancer prevention research (Philadelphia, Pa.) - 2 Feb 2024

Stan Daniela L, Kim Julian O, Schaid Daniel J, Carlson Erin E, Kim Christina A, Sinnwell Jason P, Couch Fergus J, Vachon Celine M, Cooke Andrew L, Goldenberg Benjamin A, Pruthi Sandhya

Abstract excerpt

Refinement of breast cancer risk estimates with a polygenic-risk score (PRS) may improve uptake of risk-reducing endocrine therapy (ET). A previous clinical trial assessed the influence of adding a PRS to traditional risk estimates on ET use. We stratified participants according to PRS-refined breast cancer risk and evaluated ET use and ET-related quality of life (QOL) at 1-year (previously reported) and 2-year...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Follow-Up Studies

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genetic Predisposition to Disease

Share to Genetic Risk Score

Share to Quality of Life

Share to Risk Assessment

Share to Risk Factors

Source

Identifiers

PMID: 38154464
DOI: 10.1158/1940-6207.CAPR-23-0256

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Breast Cancer Polygenic-Risk Score Influence on Risk-Reducing Endocrine Therapy Use: Genetic Risk Estimate (GENRE) Trial 1-Year and 2-Year Follow-Up.PMID 38154464Read ↗

Impact of Personalized Genetic Breast Cancer Risk Estimation With Polygenic Risk Scores on Preventive Endocrine Therapy Intention and Uptake.Semantic proximity Read ↗

Integrating breast cancer polygenic risk scores at scale in the WISDOM Study: a national randomized personalized screening trial.Semantic proximity Read ↗

A clinical pilot study for personalized risk-based breast cancer screening utilizing the polygenic risk scoreSemantic proximity Read ↗

Breast cancer polygenic risk scores: A 12-month prospective study of patient reported outcomes and risk management behaviorSemantic proximity Read ↗

Toward more personalized breast cancer risk assessment: The polygenic risk score.Semantic proximity Read ↗

A clinical pilot study for personalized risk-based breast cancer screening utilizing a polygenic risk score.Semantic proximity Read ↗

Prospective Evaluation of a Breast Cancer Risk Model Integrating Classical Risk Factors and Polygenic Risk in 15 Cohorts from Six CountriesSemantic proximity Read ↗

Breast cancer polygenic risk scores in the clinical cancer genetic counseling setting: Current practices and impact on patient management.Semantic proximity Read ↗

Prospective evaluation of a breast-cancer risk model integrating classical risk factors and polygenic risk in 15 cohorts from six countries.Semantic proximity Read ↗

Uptake of polygenic risk information among women at increased risk of breast cancer.Semantic proximity Read ↗

Personalizing Breast Cancer Screening Based on Polygenic Risk and Family History.Semantic proximity Read ↗

Cases in Precision Medicine: The Role of Polygenic Risk Scores in Breast Cancer Risk Assessment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.